Evidence map›Paper›PMID 32363002›Full record

ArticleOncotarget2020

Characterization of GRK5 as a novel regulator of rhabdomyosarcoma tumor cell growth and self-renewal.

Thao Pham, Kristin Robinson, Terra Vleeshouwer-Neumann, James E Annis, Eleanor Y Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Targeting GRK5 for Treating Chronic Degenerative Diseases.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Thao PhamDepartment of Pathology, University of Washington, Seattle, WA, USA.
Kristin RobinsonDepartment of Pathology, University of Washington, Seattle, WA, USA.
Terra Vleeshouwer-NeumannDepartment of Pathology, University of Washington, Seattle, WA, USA.
James E AnnisQuellos HTS Core, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
Eleanor Y ChenDepartment of Pathology, University of Washington, Seattle, WA, USA.
University of Washington · US

Funding

Characterizing Histone Deacetylases in RhabdomyosarcomaR01CA196882 · NCI · UNIVERSITY OF WASHINGTON · PI CHEN, ELEANOR Y · 2016 to 2020
$1.6M
NCI NIH HHS R01 CA196882
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS) is the most common soft-tissue pediatric sarcoma. Clinical outcomes for RMS patients with relapsed or metastatic disease remain poor. Treatment options remain limited, presenting an urgent need for novel therapeutic targets. Using a high-throughput siRNA screen against the human kinome, we identified GRK5, a G-protein receptor kinase, as a novel regulator of RMS tumor cell growth and self-renewal. Through functional assays

Indexed as

cell cycleGRK5, kinaserhabdomyosarcomaself-renewal

Identifiers

PMID32363002
PMCPMC7185065
OpenAlexW3020220361

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.